Deficiency of Adenosine Deaminase 2: Clinical Manifestations, Diagnosis, and Treatment

Rheum Dis Clin North Am. 2023 Nov;49(4):773-787. doi: 10.1016/j.rdc.2023.06.004. Epub 2023 Aug 1.

Abstract

Deficiency of adenosine deaminase 2 (DADA2) is a monogenic vasculitis syndrome caused by biallelic mutations in the adenosine deaminase 2 gene. The diagnosis of DADA2 is confirmed by decreased enzymatic activity of ADA2 and genetic testing. Symptoms range from cutaneous vasculitis and polyarteritis nodosa-like lesions to stroke. The vasculopathy of DADA2 can affect many organ systems, including the gastrointestinal and renal systems. Hematologic manifestations occur early with hypogammaglobulinemia, lymphopenia, pure red cell aplasia, or pancytopenia. Treatment can be challenging. Tumor necrosis factor inhibitors are helpful to control inflammatory symptoms. Hematopoietic stem cell transplant may be needed to treat refractory cytopenias, vasculopathy, or immunodeficiency.

Keywords: Adenosine deaminase 2; Autoinflammatory; DADA2; Immunodeficiency; Neutropenia; Polyarteritis nodosa (PAN); Stroke; Vasculitis.

Publication types

  • Review

MeSH terms

  • Adenosine Deaminase / genetics
  • Adenosine Deaminase / therapeutic use
  • Humans
  • Intercellular Signaling Peptides and Proteins / genetics
  • Intercellular Signaling Peptides and Proteins / therapeutic use
  • Mutation
  • Polyarteritis Nodosa* / complications
  • Vasculitis*

Substances

  • Adenosine Deaminase
  • Intercellular Signaling Peptides and Proteins

Supplementary concepts

  • deficiency of adenosine deaminase 2